这篇文章不错，转发给_老虎社区_美港股上老虎

2024-12-23

这篇文章不错，转发给大家看看

Stock Track | Bionano Genomics Soars 7.64% Pre-Market on Promising Optical Genome Mapping Study Results

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":384789396406384,"tweetId":"384789396406384","gmtCreate":1734962792818,"gmtModify":1734962794641,"author":{"id":3521442285147631,"idStr":"3521442285147631","authorId":3521442285147631,"authorIdStr":"3521442285147631","name":"SebuOba","avatar":"https://static.tigerbbs.com/b7883780849644650e2c9e643a0f9d6d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>这篇文章不错，转发给大家看看</p></body></html>","htmlText":"<html><head></head><body><p>这篇文章不错，转发给大家看看</p></body></html>","text":"这篇文章不错，转发给大家看看","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/384789396406384","repostId":1107013571,"repostType":2,"repost":{"id":"1107013571","kind":"news","weMediaInfo":{"introduction":"Track stock‘s movements and relevant news","home_visible":1,"media_name":"Stock Track","id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1734961705,"share":"https://www.laohu8.com/m/news/1107013571?lang=&edition=full","pubTime":"2024-12-23 21:48","market":"hk","language":"en","title":"Stock Track | Bionano Genomics Soars 7.64% Pre-Market on Promising Optical Genome Mapping Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1107013571","media":"Stock Track","summary":"Bionano Genomics  stock surged 7.64% in the pre-market session on Monday.The rally comes after the company announced positive results from a study at Johns Hopkins University School of Medicine, showing that its Optical Genome Mapping  technology outperformed multiple cytogenetic assays in the analysis of bone and soft tissue tumors.- OGM detected 100% of variants found by standard techniques like karyotyping and FISH. - OGM was more sensitive, detecting diagnostic variants missed by karyotyping","content":"<p>Bionano Genomics (BNGO) stock surged 7.64% in the pre-market session on Monday.</p>\n\n<p>The rally comes after the company announced positive results from a study at Johns Hopkins University School of Medicine, showing that its Optical Genome Mapping (OGM) technology outperformed multiple cytogenetic assays in the analysis of bone and soft tissue tumors. \nKey findings included:\n- OGM detected 100% of variants found by standard techniques like karyotyping and FISH\n- OGM was more sensitive, detecting diagnostic variants missed by karyotyping in 74% of failed/negative cases\n- Combined with next-generation sequencing, OGM found diagnostic variants in ~98% of cases, substantially higher than standard methods\nThe researchers highlighted OGM's potential to qualify more patients for targeted therapies or clinical trials based on the additional variants detected.\n</p>\n\n<p>The positive study results suggest increasing adoption potential for Bionano's OGM technology beyond blood cancers into solid tumor analysis as well.</p>","source":"ai_movement_en","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Bionano Genomics Soars 7.64% Pre-Market on Promising Optical Genome Mapping Study Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bionano Genomics Soars 7.64% Pre-Market on Promising Optical Genome Mapping Study Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-12-23 21:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Bionano Genomics (BNGO) stock surged 7.64% in the pre-market session on Monday.</p>\n\n<p>The rally comes after the company announced positive results from a study at Johns Hopkins University School of Medicine, showing that its Optical Genome Mapping (OGM) technology outperformed multiple cytogenetic assays in the analysis of bone and soft tissue tumors. \nKey findings included:\n- OGM detected 100% of variants found by standard techniques like karyotyping and FISH\n- OGM was more sensitive, detecting diagnostic variants missed by karyotyping in 74% of failed/negative cases\n- Combined with next-generation sequencing, OGM found diagnostic variants in ~98% of cases, substantially higher than standard methods\nThe researchers highlighted OGM's potential to qualify more patients for targeted therapies or clinical trials based on the additional variants detected.\n</p>\n\n<p>The positive study results suggest increasing adoption potential for Bionano's OGM technology beyond blood cancers into solid tumor analysis as well.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNGO":"Bionano Genomics"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107013571","content_text":"Bionano Genomics (BNGO) stock surged 7.64% in the pre-market session on Monday.\nThe rally comes after the company announced positive results from a study at Johns Hopkins University School of Medicine, showing that its Optical Genome Mapping (OGM) technology outperformed multiple cytogenetic assays in the analysis of bone and soft tissue tumors. \nKey findings included:\n- OGM detected 100% of variants found by standard techniques like karyotyping and FISH\n- OGM was more sensitive, detecting diagnostic variants missed by karyotyping in 74% of failed/negative cases\n- Combined with next-generation sequencing, OGM found diagnostic variants in ~98% of cases, substantially higher than standard methods\nThe researchers highlighted OGM's potential to qualify more patients for targeted therapies or clinical trials based on the additional variants detected.\n\nThe positive study results suggest increasing adoption potential for Bionano's OGM technology beyond blood cancers into solid tumor analysis as well.","news_type":1},"isVote":1,"tweetType":1,"viewCount":33,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":27,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/384789396406384"}